Date:2/8/2010

000 shares authorized, 2,322,750 and 7,146,500 shares issued and outstanding at December 31, 2009 and June 30, 2009, respectively 2,323 7,147 Additional paid-in capital 28,337,810 19,694,514 Statutory reserve 2,299,807 2,299,807 Treasury stock (111,587) (111,587) Retained earnings 20,393,640 16,486,775 Accumulated other comprehensive income 2,598,164 2,551,380 Total stockholders' equity 53,545,953 40,945,945 Noncontrolling interest 439,059 -- Total equity 53,985,012 40,945,945 Total liabilities and equity $58,767,047 $45,332,344 Consolidated Statements of Operations and Comprehensive Income (Unaudited) For the Three Months Ended For the Six Months Ended December 31, December 31, 2009 2008 2009 2008 Sales $14,936,378 $10,101,869 $28,341,581 $19,663,809 Cost of sales 7,177,503 4,944,980 13,526,730 9,627,603 Gross profit 7,758,875 5,156,889 14,814,851 10,036,206 Operating expenses: Selling, general and administrative 4,409,735 2,595,311 8,527,501 5,228,672 Research and development 197,380 84,220 389,870 166,858 Total operating expenses 4,607,115 2,679,531 8,917,371 5,395,530 Income from operations 3,151,760 2,477,358 5,897,480 4,640,676 Other income (expenses): Interest income (expense), net (10,443) 15,564 (1
'/>"/>

SOURCE Tianyin Pharmaceutical Co., Inc. Copyright©2010 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related biology technology :

1. Tianyin Pharmaceutical Co., Inc. Reports Record Fiscal 2009 Financials With $7.9 Million in Net Income
2. Tianyin Pharmaceutical Co., Inc. to Host Fiscal 2009 Earnings Conference Call on Thursday, September 24, 2009 at 10:30 a.m. ET
3. Tianyin Pharmaceutical Co., Inc. Obtains GMP Certification for Its New Production Facility
4. Tianyin Pharmaceutical, Co. to Present at the Rodman & Renshaw Annual Global Investment Conference on September 11 at 10:50 am ET
5. Tianyin Pharmaceutical Co., Inc. Receives Chinese SFDA Approval for Sanqi Tablets and Yinqiao Jiedu Tablets
6. Tianyin Pharmaceutical Co., Inc. Announces Cash Dividend to Common Stockholders
7. Tianyin Pharmaceutical Co., Inc. Adopts New Sales Strategy for Azithromycin Dispersible Tablets
8. Tianyin Pharmaceutical Co., Inc. to Host Fiscal Year 2009 Second Quarter Earnings Conference Call on Wednesday, February 18, 2009 at 8:45 a.m. EST
9. Tianyin Pharmaceutical Co., Inc. Implements New Sales and Marketing Strategy to Drive Revenue Growth
10. Tianyin Pharmaceutical Co., Inc. Announces First Quarter 2009 Financial Results
11. Tianyin Pharmaceutical Co., Inc. to Present at Rodman & Renshaw Annual Global Investment Conference in New York City on November 11, 2008 at 12:00 p.m. EST